There are 2867 resources available
Novel therapeutic targets and tumour agnostic treatment
Presenter: Antoine Italiano
Session: Elements to build a Molecular Tumour Board
Resources:
Slides
Webcast
Invited Discussant 729MO, 730MO and 731MO
Presenter: Inge-Marie Svane
Session: Mini Oral session: Investigational immunotherapy
Resources:
Slides
Webcast
Discussion
Presenter: All Speakers
Session: Is immunotherapy changing the standard of care in gynaecological cancers?
Resources:
Webcast
52MO - A randomized phase II trial of durvalumab and tremelIMUmab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with CHolangio- and gallbladdEr Carcinoma (IMMUCHEC)
Presenter: Arndt Vogel
Session: Mini Oral session: GI, upper digestive
Resources:
Abstract
Slides
Webcast
618O - A phase I study of TRS005: An anti-CD20-MMAE antibody-drug conjugate, in relapsed or refractory b cell non-Hodgkin lymphoma
Presenter: Yuan-Kai Shi
Session: Proffered Paper session: Haematological malignancies
Resources:
Abstract
Slides
Webcast
LBA20 - Open-label, randomized study of lasofoxifene (LAS) vs fulvestrant (Fulv) for women with locally advanced/metastatic ER+/HER2- breast cancer (mBC), an estrogen receptor 1 (ESR1) mutation, and disease progression on aromatase (AI) and cyclin-dependent kinase 4/6 (CDK4/6i) inhibitors
Presenter: Matthew Goetz
Session: Mini Oral session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
Challenges in the clinical application of Molecular Tumour Boards
Presenter: Alice Indini
Session: Elements to build a Molecular Tumour Board
Resources:
Slides
Webcast
53MO - Nal-IRI and 5-FU/LV compared to 5-FU/LV in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies (NALIRICC – AIO-HEP-0116)
Presenter: Arndt Vogel
Session: Mini Oral session: GI, upper digestive
Resources:
Abstract
Slides
Webcast
732MO - The combination of ICT01, a γ9δ2 T cell-activating mAb, plus pembrolizumab induces a broad antitumor immune response and disease control in patients with CPI-failure melanoma, NSCLC and bladder cancer: EVICTION trial
Presenter: Stephane Champiat
Session: Mini Oral session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1314O - Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer: The MetAction precision medicine study
Presenter: Anne Ree
Session: Proffered Paper session: Policy and preventive strategies
Resources:
Abstract
Slides
Webcast